Reverse Transcriptase Inhibitors

• 

  Subject Areas on Research

  • 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. 
  • 3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. 
  • A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. 
  • Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons. 
  • An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. 
  • Anti-AIDS agents. 60. Substituted 3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyldihydropyrano[2,3-f]chromone (DCP) analogues as potent anti-HIV agents. 
  • Anti-Acids Agents, 6. Salaspermic Acid, an Anti-HIV Principle from Tripterygium Wilfordii, and the Structure Activity Correlation with Its Related Compounds 
  • Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. 
  • Antiretroviral therapy effects on genetic and morphologic end points in lymphocytes and sperm of men with human immunodeficiency virus infection. 
  • Antiretroviral therapy: evaluating the new era in HIV treatment. 
  • Appropriate use of nevirapine for long-term therapy. 
  • Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the Southeastern United States. 
  • Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. 
  • Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. 
  • Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature. 
  • Combination antiretroviral therapy. 
  • Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. 
  • Compartmental transport model of microbicide delivery by an intravaginal ring. 
  • Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group. 
  • Design of tenofovir-UC781 combination microbicide vaginal gels. 
  • Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. 
  • Developmental pharmacokinetic changes of Lamivudine in infants and children. 
  • Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. 
  • Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. 
  • Drug resistance and HCV coinfection in former blood donors infected with HIV type 1 in China. 
  • Drug susceptibility and resistance mutations after first-line failure in resource limited settings. 
  • Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus. 
  • Early intensification with abacavir in subjects at high risk for incomplete viral suppression. 
  • Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry. 
  • Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. 
  • Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. 
  • Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. 
  • Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy. 
  • Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1. 
  • Growth velocity assessment in paediatric AIDS: smoothing, penalized quantile regression and the definition of growth failure. 
  • HIV infection: treatment outcomes in older and younger adults. 
  • Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. 
  • Hyperlactataemia syndromes associated with HIV therapy. 
  • Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties. 
  • Integrase inhibitors in late pregnancy and rapid HIV viral load reduction. 
  • Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. 
  • Mechanism of action and resistant profile of anti-HIV-1 coumarin derivatives. 
  • Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. 
  • Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. 
  • Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. 
  • Molecular targets of anti-HIV-1 triterpenes. 
  • Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema 
  • Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. 
  • Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. 
  • Newer treatments for HIV in children. 
  • Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. 
  • Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. 
  • Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. 
  • Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors. 
  • Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS. 
  • Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. 
  • Pediatric AIDS prognosis using somatic growth velocity. 
  • Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. 
  • Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. 
  • Pharmacokinetics and tolerance of zidovudine in preterm infants. 
  • Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. 
  • Plasma carnitine in HIV-associated neuropathy. 
  • Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. 
  • Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment. 
  • Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. 
  • Review of the use of hepatitis B core antibody-positive kidney donors. 
  • Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. 
  • Sources, mechanisms, and consequences of chemical-induced mitochondrial toxicity. 
  • Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. 
  • Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. 
  • Synthesis, Hydrolysis, and Protonation-Promoted Intramolecular Reductive Breakdown of Potential NRTIs: Stavudine α-P-Borano-γ-P-N-l-tryptophanyltriphosphates. 
  • The inhibition of human adrenal steroidogenic enzyme activities by suramin. 
  • The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. 
  • Therapy of acute and fulminant hepatitis B. 
  • Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. 
  • Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. 
  • Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. 
  • Versatility of borane nucleic acids mimics for coding, decoding and modulating genetic information. 
  • Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. 
  • Virologic response of nine therapy-experienced children receiving 64 weeks of nelfinavir salvage therapy. 
• 

  Keywords of People

  • Katz, David F., Nello L. Teer, Jr. Distinguished Professor of Biomedical Engineering, in the Edmund T. Pratt, Jr. School of Engineering, Biomedical Engineering
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology